Freestone Grove Partners LP Ardelyx, Inc. Transaction History
Freestone Grove Partners LP
- $13.4 Trillion
- Q3 2025
A detailed history of Freestone Grove Partners LP transactions in Ardelyx, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 401,755 shares of ARDX stock, worth $2.36 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
401,755
Previous 157,391
155.26%
Holding current value
$2.36 Million
Previous $617 Million
258.8%
% of portfolio
0.02%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ARDX
# of Institutions
244Shares Held
161MCall Options Held
697KPut Options Held
1.61M-
Vanguard Group Inc Valley Forge, PA18.4MShares$108 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.6MShares$103 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X013.8MShares$81.1 Million0.04% of portfolio
-
Macquarie Group LTD Australia, C310.5MShares$61.4 Million0.07% of portfolio
-
State Street Corp Boston, MA9.72MShares$57 Million0.0% of portfolio
About ARDELYX, INC.
- Ticker ARDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 154,636,000
- Market Cap $908M
- Description
- Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...